How would single payer healthcare in the US impact pharma? A pricing perspectiveThe US healthcare system is the most complicated amongst advanced industrialised countries. Health care provision is made up Share XHow would single payer healthcare in the US impact pharma? A pricing perspectivehttps://pharmaphorum.com/views-analysis-market-access/how-would-single-payer-healthcare-in-the-us-impact-pharma-a-pricing-perspective/
The biggest challenges facing rare disease pharma – and how the industry can tackle themAs Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers Share XThe biggest challenges facing rare disease pharma – and how the industry can tackle themhttps://pharmaphorum.com/r-d/views-analysis-r-d/biggest-challenges-rare-disease/
UK leaders: Takeda’s Jon NealIn the first of a new series where we talk to GMs of UK pharma divisions, managing director Share XUK leaders: Takeda’s Jon Nealhttps://pharmaphorum.com/views-analysis-market-access/uk-leaders-takeda-jon-neal/
Simple steps to better communicate NHS medicines spendLeela Barham says that there’s a communication problem when it comes to one of the most important and Share XSimple steps to better communicate NHS medicines spendhttps://pharmaphorum.com/views-analysis-market-access/simple-steps-better-communicate-nhs-medicines-spend/
Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new life into sidelined drugsOne downside of the explosion in our knowledge about potential drug targets is that many promising candidates are Share XQ&A: Fortress Biotech’s Lindsay Rosenwald on breathing new life into sidelined drugshttps://pharmaphorum.com/views-analysis-market-access/qa-fortress-biotech-on-breathing-new-life-into-sidelined-drugs/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
5 years of biosimilars in the US: what have we learned?Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients Share X5 years of biosimilars in the US: what have we learned?https://pharmaphorum.com/views-analysis-market-access/5-years-of-biosimilars-in-the-us-what-have-we-learned/
Making real world evidence fit for purposeAlthough real world evidence (RWE) is a hot topic in pharma right now, many still question whether it Share XMaking real world evidence fit for purposehttps://pharmaphorum.com/views-analysis-market-access/making-real-world-evidence-fit-for-purpose/
Future prospects for an Innovative Medicines Fund for EnglandOn the 12 December 2019, the UK general public voted for a further five years of Conservative government. Share XFuture prospects for an Innovative Medicines Fund for Englandhttps://pharmaphorum.com/views-analysis-market-access/future-prospects-for-an-innovative-medicines-fund-for-england/
